updat model conform management guidanc rais
adj ep estim toward mid-point rang notabl think management
guidanc could prove conserv see potenti upsid synergi
enterpris modern contribut adj ep gener
updat model reflect management guidanc metric estim adj ep
y/i toward mid-point guidanc rang
also estim adj oper incom y/i specif
estim adj oper incom y/i pharmaci servic
y/i retail/ltc y/i benefit
think guidanc could prove conserv given overexecut
evidenc realiz synergi ahead origin expect
also led pullforward think could upsid faster
expect synergi realiz well upsid synergi target
also surpris faster expect realiz management enterpris
modern target note synergi primarili benefit
hcb segment enterpris modern primarili benefit retail/ltc
pharmaci servic segment anoth sourc potenti upsid guidanc prior period
develop recal realiz net realiz capit
gain amount almost oper incom addit think
could upsid gener improv outlook gener better
expect procur benefit well given redoak jv lastli
market leader specialti pharmaci think could also upsid specialti
strength drug distributor
rais adj ep estim
respect also rais price target base revis
dcf analysi impli share trade adj ep estim
pleas see page report import disclosur
posit long-term strategi coordin care combin
legaci asset aet broader healthcar system continu transit toward
value-bas care believ potenti bring differenti model
market gain share and/or improv profit demonstr
valu proposit market management believ improv outcom lower cost
manag chronic condit use healthhub leverag telemedicin non-
physician provid furthermor view share under-valued current level
progress integr aet
merger achiev synergi target
increment inform l-t
strategi potenti revenu
top-lin growth
adj oper margin almost
slightli y/i margin compress slightli
across segment
assum share repo
top-lin growth greater due
higher expect volum pbm
retail/ltc
adj oper margin higher
expect benefit faster
synergies/enterpris modern
greater contribut gener
top-lin growth weaker due
lower expect volum pbm
adj oper margin lower
expect slower synergies/
enterpris modern lower
contribut gener
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
million except per-shar data
cowen compani
interseg net good interseg net cost good benefit interseg net benefit gross gross bp chang y/y- oper oper oper bp chang y/y- adj oper adj oper bp chang y/y- interest expens pre-tax pre-tax bp chang y/y- adj incom tax provis effect tax rate effect tax adj net adj net incom bp chang y/y- earn alloc particip net incom attribut non-controlling adj net incom attribut net weight averag dilut share adj cowen
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work terminal- valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
cowen compani
interseg net good interseg net cost good benefit interseg net benefit gross gross chang y/y- oper oper chang y/y- adj oper adj oper chang y/y- interest expens pre-tax pre-tax chang y/y- adj incom tax provis effect tax rate tax net adj net incom chang y/y- earn alloc particip net incom attribut non-controlling adj net incom attribut net weight averag dilut share adj chang y/i net oper net net incom attribut end decemb cowen
million except per-shar data
cowen compani
interseg net good interseg net cost good benefit interseg net benefit gross gross chang oper oper chang adj oper adj oper chang interest expens pre-tax pre-tax chang adj incom tax provis effect tax rate tax net adj net incom chang earn alloc particip net incom attribut non-controlling adj net incom attribut net weight averag dilut share adj chang y/i net oper net net incom attribut cowen
million
cowen compani
cash short-term account receiv current current long-term properti equip oper leas right-of-us assets- intang asset separ account assets- total liabil account pharmaci claim discount care cost policyhold funds- accru insur current portion oper leas liabilities- short-term current portion long-term current long-term long-term oper leas liabilities- defer incom separ account liabilities- long-term insur long-term redeem non-controlling interest- stockhold equiti common treasuri retain accumul comprehens total sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale day purchas account day claim day ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti decemb cowen
million
compani report cowen compani
income/ loss adjust requir reconcil net incom net cash provid oper activ depreci goodwil impairments- loss settlement defin benefit pension plans- stock-bas loss sale loss earli extinguish defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv account payabl claim discount care cost payabl insur long-term net cash oper acquisit proce sale subsidiari assets- properti acquisit issuanc common purchas treasuri stock- dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival restrict cash begin cash equival restrict cash end cowen summari capit owner financ non-recur exclud non-recur itemsyear end decemb cowen
million
compani report cowen compani
activitiesnet adjust requir reconcil net incom net cash provid oper activ depreci goodwil impairments- loss settlement defin benefit pension plans- stock-bas loss sale subsidiary- loss earli extinguish defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv account payabl pharmaci claim discount care cost payabl insur long-term net cash provid oper invest activitiesproce sale matur purchas purchas properti proce sale-lease-back acquisit net cash proce sale subsidiari assets- net cash use invest financ activitiesincreas decreas short-term proce issuanc long-term repay long-term purchas non-controlling interest payment conting deriv settlements- dividend proce exercis stock payment tax relat net share settlement equiti repurchas common net cash provid use financ effect exchang rate net decreas cash cash cash equival restrict cash begin cash equival restrict cash end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
slower expect realiz integr synergi and/or enterpris
modern benefit lower expect benefit transform initi
political/regulatori chang advers affect signific contract loss
